Navidea Biopharmaceuticals, Inc. (NAVB)

NAVB Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Year	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012 - 1992
Net Income	-17.22	-11.73	-10.64	-10.95	-16.13	74.95	-14.31	-27.56	-35.73	-42.7	Upgrade
Depreciation & Amortization	0.1	0.08	0.07	0.14	0.15	0.25	0.5	0.57	0.5	0.4	Upgrade
Share-Based Compensation	0.3	0.47	0.23	0.23	0.31	0.39	0.28	2.37	1.63	2.91	Upgrade
Other Operating Activities	7.83	0.96	2.17	1.21	19.94	-16.51	17.09	5.55	4.47	3.77	Upgrade
Operating Cash Flow	-8.99	-10.22	-8.17	-9.35	4.28	59.08	3.56	-19.08	-29.13	-35.61	Upgrade
Operating Cash Flow Growth	-	-	-	-	-92.76%	1561.15%	-	-	-	-	Upgrade
Capital Expenditures	-0.39	-0.33	-0.41	-0.06	-0.05	-0.03	-0	-0.07	-1.19	-1.29	Upgrade
Acquisitions	0	0	0	0	0.05	39.22	0	0	0	0	Upgrade
Change in Investments	-	-	-	-0.8	-2.2	-2.6	-0.03	-	-0.33	-	Upgrade
Other Investing Activities	-	-	0	1.63	3.15	-38.42	-0.01	0.04	-	-	Upgrade
Investing Cash Flow	-0.39	-0.33	-0.41	0.77	0.95	-1.83	-0.04	-0.03	-1.52	-1.29	Upgrade
Dividends Paid	0	-0.02	0	0	0	0	0	0	0	0	Upgrade
Common Stock Issued	0	0	4.44	7.09	3	0.07	13.64	0.07	0.09	41.3	Upgrade
Share Repurchases	0	-0.02	0	0	0	0	0	0	0	0	Upgrade
Other Financing Activities	7.14	12.1	5.77	-0.93	-7.55	-56.07	-22.78	20.73	3.1	19.42	Upgrade
Financing Cash Flow	7.14	12.11	10.21	6.16	-4.55	-55.99	-9.14	20.79	3.19	60.72	Upgrade
Net Cash Flow	-2.24	1.56	1.62	-2.43	0.68	1.26	-5.63	1.69	-27.46	23.82	Upgrade
Free Cash Flow	-9.38	-10.55	-8.59	-9.41	4.23	59.05	3.55	-19.14	-30.32	-36.9	Upgrade
Free Cash Flow Growth	-	-	-	-	-92.84%	1561.07%	-	-	-	-	Upgrade
Free Cash Flow Margin	-14282.76%	-1984.44%	-938.53%	-35357.39%	1311.31%	3261.64%	16.18%	-144.48%	-483.17%	-3264.06%	Upgrade
Free Cash Flow Per Share	-0.32	-0.36	-0.36	-0.65	0.50	7.11	0.46	-2.53	-4.08	-6.06	Upgrade

Sources: The data provider is Financial Modeling Prep and the numbers are sourced from SEC filings.